Incyte
INCY
113.44
+0.71
+0.63%
Incyte
US · INCY
#803 by market cap
Listed 1970
113.44
+0.71
+0.63%
Live - 5344 symbols - heartbeat 361s ago
· 2026-10-08 07:00
Pre-market
112.86
-0.51%
After-hours
111.97
-1.30%
Overnight
113.45
+0.01%
- Market cap
- 22.99B
- P/E (TTM)i
- 14.45
- P/Bi
- 3.62
- EPSi
- 6.41
- Div yieldi
- 0.00%
- 52W posi
- 62%
Reader sentiment
Are you bullish or bearish on INCY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 9.73, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +21.22% YoY
Margins
- Gross margin
- 92.76%
- Operating margin
- 26.12%
- Net margin
- 25.03%
Key ratios & quality
- PEG ratioi
- 0.26
- Altman Z-Scorei
- 9.73
PEG uses trailing P/E against the 3-year net income growth rate (55.73%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.88B | 2.16B | 2.67B | 2.99B | 3.39B | 3.70B | 4.24B | 5.14B |
| Gross profit | 1.79B | 2.04B | 2.54B | 2.84B | 3.19B | 3.44B | 3.93B | 4.77B |
| Selling & admin expenses | 434.41M | 468.71M | 516.90M | 739.56M | 1.00B | 1.16B | 1.22B | 1.38B |
| Research & development | 1.20B | 1.15B | 2.22B | 1.46B | 1.59B | 1.63B | 2.61B | 2.05B |
| Operating profit | 155.40M | 421.69M | -240.24M | 600.52M | 591.63M | 655.36M | 101.29M | 1.34B |
| Pretax profit | 115.35M | 486.79M | -232.22M | 570.44M | 529.12M | 834.22M | 316.63M | 1.66B |
| Tax | 5.85M | 39.89M | 63.48M | -378.14M | 188.46M | 236.62M | 284.02M | 377.80M |
| Net profit | 109.49M | 446.91M | -295.70M | 948.58M | 340.66M | 597.60M | 32.62M | 1.29B |
| Basic EPS | 1 | 2 | -1 | 4 | 2 | 3 | 0 | 7 |
| Diluted EPS | 0.51 | 2.05 | -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.05B | 1.22B | 1.37B | 1.51B | 1.27B | 1.67B |
| Gross profit | 979.70M | 1.14B | 1.27B | 1.39B | 1.17B | 1.57B |
| Selling & admin expenses | 325.70M | 331.00M | 329.10M | 390.40M | 328.10M | 351.70M |
| Research & development | 437.28M | 494.92M | 506.58M | 611.37M | 515.90M | 516.95M |
| Operating profit | 216.72M | 310.81M | 431.30M | 383.96M | 324.17M | 700.39M |
| Pretax profit | 234.19M | 558.01M | 482.31M | 389.94M | 343.60M | 751.51M |
| Tax | 75.99M | 153.01M | 58.14M | 90.66M | 40.27M | 165.91M |
| Net profit | 158.20M | 405.00M | 424.17M | 299.28M | 303.33M | 585.61M |
| Basic EPS | 1 | 2 | 2 | 2 | 2 | 3 |
| Diluted EPS | 0.80 | 2.04 | 2.11 | 1.46 | 1.47 | 2.81 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.83B | 2.48B | 2.36B | 3.12B | 4.09B | 4.65B | 3.24B | 5.02B |
| Cash & ST investments | 1.44B | 2.12B | 1.80B | 2.35B | 3.24B | 3.66B | 2.16B | 3.58B |
| Inventory | 6.97M | 11.40M | 16.43M | 27.90M | 42.00M | 62.97M | 58.87M | 101.06M |
| Total assets | 2.65B | 3.43B | 3.56B | 4.93B | 5.84B | 6.78B | 5.44B | 6.96B |
| Total current liabilities | 425.28M | 513.34M | 631.20M | 854.31M | 1.16B | 1.24B | 1.64B | 1.52B |
| Short-term debt | 18.70M | 28.31M | 14.96M | 13.19M | 11.37M | 9.13M | 10.00M | 10.21M |
| Long-term debt | 17.43M | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 719,795,000.00 | 828,344,000.00 | 949,650,000.00 | 1,163,348,000.00 | 1,470,865,000.00 | 1,592,270,000.00 | 1,996,694,000.00 | 1,790,495,000.00 |
| Total equity | 1.93B | 2.60B | 2.61B | 3.77B | 4.37B | 5.19B | 3.45B | 5.17B |
| Retained earnings | -1.88B | -1.43B | -1.73B | -777.87M | -437.21M | 160.39M | -1.07B | 213.77M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.51B | 3.64B | 4.28B | 5.02B | 5.48B | 6.03B |
| Cash & ST investments | 2.41B | 2.42B | 2.93B | 3.58B | 4.02B | 4.54B |
| Inventory | 63.98M | 83.42M | 83.45M | 101.06M | 115.62M | 112.54M |
| Total assets | 5.75B | 5.82B | 6.33B | 6.96B | 7.34B | 7.87B |
| Total current liabilities | 1.72B | 1.28B | 1.34B | 1.52B | 1.49B | 1.31B |
| Short-term debt | 10.48M | 10.65M | 10.39M | 10.21M | 10.02M | 9.85M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 2,081,802,000.00 | 1,650,451,000.00 | 1,679,162,000.00 | 1,790,495,000.00 | 1,716,266,000.00 | 1,528,220,000.00 |
| Total equity | 3.67B | 4.17B | 4.65B | 5.17B | 5.62B | 6.34B |
| Retained earnings | -914.68M | -509.68M | -85.51M | 213.77M | 517.10M | 1.10B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 336.23M | 710.66M | -124.60M | 749.49M | 969.94M | 496.49M | 335.34M | 1.41B |
| Depreciation & amortization | 54.97M | 54.53M | 51.81M | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M |
| Free cash flow | 262.74M | 632.59M | -311.98M | 568.48M | 892.11M | 449.00M | 235.17M | 1.33B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -2.00B | 0 |
| Ending cash balance | 1.16B | 1.83B | 1.51B | 2.06B | 2.95B | 3.22B | 1.69B | 3.10B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 266.07M | 44.74M | 559.39M | 543.30M | 369.35M | 507.66M |
| Depreciation & amortization | 22.36M | 22.92M | 24.02M | 23.98M | 23.80M | 26.48M |
| Free cash flow | 262.90M | 25.67M | 519.64M | 521.42M | 354.15M | 495.25M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 1.94B | 1.96B | 2.46B | 3.10B | 3.46B | 3.98B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 6.16 | 19.76 | -11.35 | 29.73 | 8.37 | 12.50 | 0.76 | 29.87 |
| ROA %i | 4.43 | 14.72 | -8.46 | 22.33 | 6.32 | 9.47 | 0.53 | 20.75 |
| ROIC %i | 6.14 | 19.42 | -11.06 | 29.35 | 8.32 | 9.88 | -1.54 | 27.75 |
| 5-year avg ROE %i | -- | 9.05 | 3.86 | 2.75 | 10.53 | 11.80 | 8.00 | 16.25 |
| EBIT margin %i | 6.21 | 22.64 | -8.63 | 19.17 | 15.67 | 22.64 | 7.52 | 32.42 |
| FCF / sales %i | 13.96 | 29.30 | -- | 19.04 | 26.28 | 12.15 | 5.55 | 25.86 |
| Current ratioi | 4.31 | 4.83 | 3.74 | 3.65 | 3.54 | 3.75 | 1.97 | 3.32 |
| Quick ratioi | 4.11 | 4.73 | 3.62 | 3.47 | 3.36 | 3.55 | 1.83 | 3.04 |
| Debt / assetsi | 1.37 | 1.76 | 1.33 | 0.91 | 0.71 | 0.56 | 0.80 | 0.58 |
| LT debt / equityi | 0.91 | 1.23 | 1.25 | 0.84 | 0.69 | 0.56 | 0.97 | 0.58 |
| Interest coveragei | 75.76 | 263.42 | -105.82 | 299.97 | 199.47 | 328.01 | 139.87 | 686.52 |
| Revenue CAGR (3Y) %i | 35.66 | 24.98 | 20.18 | 16.64 | 16.29 | 11.49 | 12.41 | 14.84 |
| Net income CAGR (3Y) %i | 155.94 | 62.46 | -- | 105.38 | -8.65 | -- | -67.48 | 55.73 |
| FCF CAGR (3Y) %i | 60.62 | 50.80 | -- | 29.34 | 12.14 | -- | -25.49 | 14.23 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 0.47 | 24.30 | 30.39 | 29.87 | 30.82 | 30.67 |
| ROA %i | 0.33 | 16.61 | 20.96 | 20.75 | 21.88 | 23.55 |
| ROIC %i | -1.30 | 22.39 | 28.31 | 27.75 | 28.59 | 28.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.19 | 27.59 | 33.05 | 32.42 | 33.13 | 33.85 |
| FCF / sales %i | 6.54 | 20.62 | 24.35 | 25.86 | 26.50 | 32.48 |
| Current ratioi | 2.04 | 2.85 | 3.20 | 3.32 | 3.68 | 4.59 |
| Quick ratioi | 1.88 | 2.55 | 2.86 | 3.04 | 3.40 | 4.31 |
| Debt / assetsi | 0.75 | 0.73 | 0.65 | 0.58 | 0.54 | 0.49 |
| LT debt / equityi | 0.89 | 0.76 | 0.66 | 0.58 | 0.52 | 0.45 |
| Interest coveragei | 126.36 | 516.92 | 702.21 | 686.52 | 760.03 | 847.18 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Global discovery, development and commercialization of proprietary therapeutics100.00%
Quote time 2026-10-08 07:00:03 · For reference only, not investment advice and not tailored to your situation.